Fig 1.
A. Graph showing the number of participants who completed the survey and those who did not. B. Graph showing the countries in which the study participants practice. C. A pie chart showing the distribution of participants who practiced in Canada according to provinces. D. Graph showing the hospital setting in which participants practice. E. Graph showing the type of medicine practiced by participants.
Fig 2.
Reported annual number of toxicosis cases before and after October 2018.
A. All reported annual cannabis toxicosis cases pre- and post-legalization. Inset: Species in which cannabis toxicosis was observed and the number of participants who reported them. B. Reported annual cannabis toxicosis cases pre- and post-legalization in Canada. C. Reported annual cannabis toxicosis cases before and after October 2018 in the US. D. Reported annual cannabis toxicosis cases pre- and post-legalization in urban settings. E. Reported annual cannabis toxicosis cases pre- and post-legalization in sub-urban settings. F. Reported annual cannabis toxicosis cases pre- and post-legalization in rural settings. G. Reported annual cannabis toxicosis cases pre- and post-legalization by participants who practice emergency medicine. H. Reported annual cannabis toxicosis cases pre- and post-legalization by participants who practice general medicine. I. Reported annual cannabis toxicosis cases pre- and post-legalization by participants who practice other types of medicine. Vets: Number of veterinarians who reported being presented with cannabis toxicosis in a particular species.
Fig 3.
Changes in annual cannabis toxicosis case numbers reported by each participant.
A. Graph showing changes in annual cannabis toxicosis case numbers reported by all participants. Insets: Pie chart showing number of participants who reported equal annual number of cases pre- and post-legalization (no change) and those who reported different annual numbers of cases pre- and post-legalization (change) B. Changes in annual cannabis toxicosis case numbers reported by participants in Canada. C. Changes in annual cannabis toxicosis case numbers reported by participants in the US. Increase: participants who reported increases in annual numbers of cannabis toxicosis cases pre- and post-legalization; Decrease: participants who reported decreases in annual numbers of cannabis toxicosis cases pre- and post-legalization. Inset pie chart: No change: participants who reported equal annual numbers of cannabis toxicosis cases pre- and post-legalization; Change: participants who reported different annual numbers of cannabis toxicosis cases pre- and post-legalization.
Table 1.
Aggregate data about cannabis toxicosis clinical signs and their frequencies reported by Canadian and American veterinarians.
Fig 4.
Products that caused cannabis toxicosis, their routes of exposure, and reasons for exposure.
A. Graph showing the products that were reported to cause cannabis toxicosis by the study participants. B. Graph showing other products that were reported to cause cannabis toxicosis by the study participants. C. Graph showing the route of exposure to the products that caused cannabis toxicosis. D. Graph showing the reasons for exposure to the products that caused cannabis toxicosis.
Fig 5.
Diagnosis and treatments for cannabis toxicosis, and deaths associated with cannabis toxicosis and their causes.
A. Graph showing methods used by participants to diagnose cannabis toxicosis. B. Graph showing various treatments for cannabis toxicosis reported by participants. C. Graph showing treatment duration following cannabis toxicosis. D. Graph showing cost of treatment for cannabis toxicosis. E. Graph showing the number of participants who either reported deaths or no deaths associated with cannabis toxicosis in pets. F. Graph showing the causes of deaths reportedly associated with cannabis toxicosis.